Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium
Portfolio Pulse from
Celcuity presented promising overall survival data from a Phase 1b study at the 2024 San Antonio Breast Cancer Symposium. The study evaluated Gedatolisib in combination with Palbociclib and endocrine therapy, showing a median overall survival of 77.3 months for treatment-naïve HR+, HER2- advanced breast cancer patients.
December 11, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Celcuity's presentation of positive overall survival data from its Phase 1b study could boost investor confidence and potentially impact the stock price positively.
The positive data from the Phase 1b study suggests that Gedatolisib, in combination with Palbociclib and endocrine therapy, is effective in extending overall survival for HR+, HER2- advanced breast cancer patients. This could lead to increased investor confidence and a positive impact on Celcuity's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90